US20010021863A1 - Device and method providing atrial anti-tachyarrhythmia therapy - Google Patents
Device and method providing atrial anti-tachyarrhythmia therapy Download PDFInfo
- Publication number
- US20010021863A1 US20010021863A1 US09/852,513 US85251301A US2001021863A1 US 20010021863 A1 US20010021863 A1 US 20010021863A1 US 85251301 A US85251301 A US 85251301A US 2001021863 A1 US2001021863 A1 US 2001021863A1
- Authority
- US
- United States
- Prior art keywords
- ventricular
- tachyarrhythmia
- therapy
- time delay
- heart
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/3621—Heart stimulators for treating or preventing abnormally high heart rate
- A61N1/3622—Heart stimulators for treating or preventing abnormally high heart rate comprising two or more electrodes co-operating with different heart regions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/38—Applying electric currents by contact electrodes alternating or intermittent currents for producing shock effects
- A61N1/39—Heart defibrillators
- A61N1/3956—Implantable devices for applying electric shocks to the heart, e.g. for cardioversion
- A61N1/3962—Implantable devices for applying electric shocks to the heart, e.g. for cardioversion in combination with another heart therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/38—Applying electric currents by contact electrodes alternating or intermittent currents for producing shock effects
- A61N1/39—Heart defibrillators
- A61N1/3956—Implantable devices for applying electric shocks to the heart, e.g. for cardioversion
- A61N1/3962—Implantable devices for applying electric shocks to the heart, e.g. for cardioversion in combination with another heart therapy
- A61N1/39622—Pacing therapy
Definitions
- This invention relates generally to cardiac rhythm management devices and methods, and more particularly to an implantable device, such as a cardioverter-defibrillator, and method for ting atrial tachyarrhythmias.
- Atrial tachyarrhythmias are quite common, and are seen even in patients who are not acutely ill.
- One such atrial tachyarrhythmia, atrial fibrillation does not usually pose an immediate threat to the patient's life, but prolonged atrial fibrillation can compromise patient hemodynamics. Inadequate blood flow due to atrial fibrillation may lead to blood clots, which increase the risk of strokes. Other symptoms may include palpitations of the heart, dizziness, or loss of consciousness.
- One method of treating atrial fibrillation is to deliver a countershock to terminate the arrhythmia.
- the countershock may be applied via an external or inplantable defibrillator.
- this method of treating atrial fibrillation risks causing ventricular tachyarrhythmias, including life-threatening ventricular fibrillation.
- One method of reducing the risk of ventricular fibrillation is by synchronizing the delivery of a countershock to an electrical ventricular activation (R-wave) of the heart.
- R-wave electrical ventricular activation
- the present invention provides a method of applying anti-tachyarrhythmia therapy, such as a countershock, to the heart. From the atrium of the heart, atrial activity needing anti-tachyarrhythmia therapy is detected. Ventricular activity is monitored for an indication of abnormal susceptibility to ventricular tachyarrhythmia. Anti-tachyarrhythmia therapy is delivered to the atrium in response to the detected atrial tachyarrhythmia activity. But the atrial tachyarrhythmia therapy is delayed for a first time delay if the indication of abnormal susceptibility to ventricular tachyarrhythmia is detected.
- anti-tachyarrhythmia therapy such as a countershock
- the present invention also provides an device, such as an implantable cardioverter-fibrillator, for delivering anti-tachyarrhythmia therapy to the heart.
- An atrial receiver receives an atrial heart activity signal from an atrium of the heart.
- a ventricular receiver receives a ventricular heart activity signal from the ventricle of the heart.
- a controller controls the delivery of the anti-tachyarrhythmia therapy to the atrium in response to the atrial heart activity signal indicating a need for the anti-tachyarrhythmia therapy.
- the controller includes a first timer for delaying the delivery, by a first time delay, of the anti-tachyarrhythmia therapy to the atrium in response to the ventricular heart activity signal indicating abnormal susceptibility to a ventricular tachyarrhythmia.
- the present invention delays delivery of atrial anti-tachyarrhythmia therapy when an indication of abnormal susceptibility to a ventricular tachyarrhythmia is present. As a result, the present invention reduces the risk of reinducing ventricular tachyarrhythmias, such as life-threatening ventricular fibrillation, which can be caused by the delivery of anti-tachyarrhythmia therapy to the atrium.
- FIG. 2 is a flow chart illustrating an alternate embodiment of the method illustrated in FIG. 1, in which a first time delay is adjusted according to a type of indication of abnormal susceptibility to ventricular tachyarrhythmia.
- FIG. 4 is a flow chart illustrating an alternate embodiment of the method illustrated in FIG. 1, in which a first timer is reset after delivery of anti-tachyarrhythmia therapy to the atrium.
- FIG. 5 is a flow chart illustrating, in more detail, one embodiment of the step of delivering the atrial anti-tachyarrhythmia therapy in FIGS. 1 - 4 .
- FIG. 6 is a schematic diagram illustrating one embodiment of the present invention in relation to a heart to which it delivers therapy.
- the present invention provides anti-tachyarrhythmia therapy to an atrium of a heart.
- atrial tachyarrhythmias are understood to comprise any atrial tachyarrhythmia including, but not limited to: sinus tachycardia, atrial flutter, atrial tachycardia, atrial fibrillation, AV nodal reentrant tachycardia.
- Ventricular tachyarrhythmias (VTs) are understood to comprise any ventricular tachyarrhythmia including, but not limited to, ventricular fibrillation (VF).
- Cardioversion and defibrillation are understood to refer generally to any treatment of a cardiac arrhythmia by an electrical countershock.
- Cardioverter and defibrillator are understood to refer generally to any device capable of treating a cardiac arrhythmia through an electrical countershock.
- Anti-tachyarrhythmia therapy is understood to comprise treatment of atrial tachyarrhythmia by electrical countershock, anti-tachyarrhythmia drugs, or anti-tachycardia pacing.
- the present invention provides anti-tachyarrhythmia therapy, such as countershock therapy, to the atrium of the heart such that the risk of ventricular tachyarrhythmias, particularly that of life-threatening ventricular fibrillation, is minimized.
- anti-tachyarrhythmia therapy such as countershock therapy
- the present invention recognizes time periods in which the ventricle of the heart may be abnormally susceptible to ventricular tachyarrhythmias, and avoids treatment of atrial tachyarrhythmias during these vulnerable periods.
- FIG. 1 is a flow chart illustrating one embodiment of the method according to the present invention.
- a first timer for measuring a first time delay is initially reset at step 100 .
- An atrium of the heart and a ventricle of the heart are concurrently and continuously monitored at steps 110 A-B.
- the atrium is monitored for any atrial tachyarrhythmia activity needing anti-tachyarrhythmia therapy, such as atrial fibrillation.
- the ventricle is monitored for any ventricular vulnerability, i.e. any indication of abnormal susceptibility to a ventricular tachyarrhythmia (VT), and particularly for abnormal susceptibility to ventricular fibrillation (VF).
- VT ventricular tachyarrhythmia
- VF ventricular fibrillation
- Sensed electrical indications of abnormal susceptibility to a ventricular tachyarrhythmia may include, but are not limited to: one or more premature ventricular contractions (PVCs); a particular number of premature ventricular contractions detected during a particular third period of time, such as, for example, 6 to 8 premature ventricular contractions occurring within an hour, a particular number of successive premature ventricular contractions; ventricular tachycardia bigeminy; non-sustained monomorphic or polymorphic ventricular tachycardia; sustained monomorphic or polymorphic ventricular tachycardia; and, ventricular fibrillation.
- PVCs premature ventricular contractions
- a particular number of premature ventricular contractions detected during a particular third period of time such as, for example, 6 to 8 premature ventricular contractions occurring within an hour, a particular number of successive premature ventricular contractions
- ventricular tachycardia bigeminy non-sustained monomorphic or polymorphic ventricular tachycardia
- Indications of ventricular abnormal susceptibility are understood to include actual instances of ventricular tachyarrhythmia, including ventricular fibrillation, and any other indication of abnormal susceptibility to ventricular tachyarrhythmia
- other suitable indications of abnormal susceptibility to ventricular tachyarrhythmia may include chemical or other indications.
- the actual delivery of atrial anti-tachyarrhythmia therapy, such as a countershock is itself defined as an indication of abnormal susceptibility to ventricular tachyarrhythmia.
- Indications of abnormal susceptibility to ventricular tachyarrhythmia are understood not to include the T-wave time periods within a cardiac cycle during which the heart is normally particularly vulnerable to an external stimulus. However, in one embodiment of the present invention that is described below, such normal time periods of vulnerability are also avoided by the present invention. It is also understood that the indications of abnormal susceptibility to ventricular tachyarrhythmia are progammably adjustable by the physician. Thus, those indications of susceptibility to ventricular tachyarrhythmia that are considered abnormal may vary from patient to patient.
- One aspect of the present invention is the recognition that such indications of abnormal susceptibility to ventricular tachyarrhythmia define time periods in which the heart is metabolically abnormally susceptible to induction of ventricular tachyarrhythmias, including life-threatening ventricular fibrillation. As described in detail below, the present invention avoids delivering anti-tachyarrhythmia therapy, such as countershock treatment, to the atrium during these vulnerable time periods.
- anti-tachyarrhythmia therapy such as countershock treatment
- step 140 if the ongoing atrial monitoring of step 110 A provides no indication of a detected atrial tachyarrhythmia, the ongoing monitoring of the atrium and ventricle continues at concurrent steps 110 A-B.
- the atrial monitoring indicates detection of an atrial tachyarrhythmia
- the present invention is typically capable of recognizing and distinguishing, at step 145 , between different forms of atrial tachyarrhythmia detected at step 140 , such that anti-tachyarrhythmia therapy is only delivered in response to particular forms of atrial tachyarrhythmia, e.g. atrial fibrillation (AF), as described below.
- AF atrial fibrillation
- the first timer for measuring the first time delay is checked at step 150 . If the first time delay is expired (i.e., if the first timer's measurement of the elapsed time from the last indication of abnormal susceptibility to ventricular tachyarrhythmia, if any, exceeds the programmably adjustable value of the first time delay), a countershock or other anti-tachyarrhythmia therapy is delivered at step 160 to the atrium in which the atrial tachyarrhythmia was detected.
- anti-tachyarrhythmia therapy is delayed at step 170 until the first time delay has expired.
- the countershock or other anti-tachyarrhythmia therapy is delivered to the atrium at step 160 .
- the ongoing monitoring of the atrium and the ventricle may be optionally blanked during delivery of the anti-tachyarrhythmia therapy at step 110 , but the ongoing monitoring continues following the delivery of the anti-tachyarrhythmia therapy to the atrium at step 160 .
- the first time delay is typically programmably adjusted by the physician to accommodate the individual degree of metabolic vulnerability of the patient to ventricular tachyarrhythmia, including ventricular fibrillation.
- the metabolic vulnerability of the particular patient to ventricular tachyarrhythmia, including ventricular fibrillation will vary widely.
- the duration of the first time delay which follows the above-described indications of abnormal susceptibility to ventricular tachyarrhythmia, will also vary widely to accommodate this variability in the patient population.
- the period of metabolic vulnerability that the first time delay should exceed is typically longer than the duration of a cardiac cycle, i.e. time between successive heartbeats. Therefore, the first time delay is typically adjustably programmed to a value exceeding one second. The first time delay may even be programmed to exceed one hour or several hours for patients that are abnormally metabolically vulnerable to ventricular tachyarrhythmia, such as ventricular fibrillation, following recent indications of abnormal susceptibility to ventricular tachyarrhythmia.
- FIG. 2 is a flow chart illustrating one embodiment of the present invention in which the duration of the first time delay depends on the particular type of one or more recent particular indications of abnormal susceptibility to ventricular tachyarrhythmia.
- This embodiment allows the physician to independently program different values of the first time delay to correspond respectively to different types of indications of abnormal susceptibility to ventricular tachyarrhythmia.
- one indication of abnormal susceptibility to ventricular tachyarrhythmia may be a single premature ventricular contraction, for which the physician may program a corresponding first time delay to be several seconds.
- Another indication of abnormal susceptibility to ventricular tachyarrhythmia may be an actual episode of ventricular fibrillation, for which the physician may program a corresponding first time delay to be several hours.
- the invention recognizes the type of the most recent indication of abnormal susceptibility to ventricular tachyarrhythmia, and sets the value of the first time delay accordingly, unless doing so would cut short an unexpired longer first time delay corresponding to a previous indication of abnormal susceptibility to ventricular tachyarrhythmia.
- the invention then resets the first timer at step 100 before continuing the ongoing monitoring of the atrium and the ventricle at concurrent steps 110 A-B.
- FIG. 3 is a flow chart illustrating an alternate embodiment of the method according to the present invention.
- the method illustrated in FIG. 3 closely follows that illustrated and described above with respect to FIG. 1, and like blocks or steps are indicated by the like numbers.
- the present invention rechecks whether atrial tachyarrhythmia is detected at step 140 . If atrial tachyarrhythmia is not present at step 140 , or is determined at step 145 to be of a type not requiring treatment, the ongoing monitoring of the atrium and the ventricle is resumed at concurrent steps 110 A-B.
- the invention finds the first time delay to be expired at step 150 , and proceeds to deliver anti-tachyarrhythmia therapy, such as a countershock, to the atrium at step 160 .
- anti-tachyarrhythmia therapy such as a countershock
- FIG. 4 is a flow chart illustrating an alternate embodiment of the method according to the present invention.
- the method illustrated in FIG. 4 closely follows that illustrated and described above with respect to FIG. 1, and like blocks or steps are indicated by the like numbers.
- the timer for measuring the first time delay is reset at step 100 before the ongoing monitoring of the atrium and ventricle continues at concurrent steps 110 A-B.
- subsequent atrial anti-tachyarrhythmia therapy is delayed by at least the first time delay regardless of whether or not ventricular tachyarrhythmia is indicated at step 120 .
- subsequent atrial anti-tachyarrhythmia therapy can be delivered immediately, i.e. without waiting for the duration of first time delay, if ventricular tachyarrhythmia is not indicated subsequent to a first delivery of atrial anti-tachyarrhythmia therapy.
- FIG. 5 is a flow chart illustrating, by way of example, one embodiment of the details of step 160 in more detail. The method illustrated in FIG. 5 closely follows that illustrated and described above with resect to FIG. 1, and like blocks or steps are indicated by the like numbers. However, the additional details of step 160 that are illustrated in FIG. 5 may also be applicable to other embodiments of the present invention, such as those illustrated in FIGS. 1 - 4 .
- delivery of anti-tachyarrhythmia therapy at step 160 includes synchronizing to one of the ventricular activations (R-waves) of the heart, at step 500 .
- Such ventricular activations are detected during the ongoing monitoring of the ventricle at step 110 B.
- Synchronizing the delivery of the anti-tachyarrhythmia therapy to one of the ventricular activations reduces the risk of delivering a countershock to the heart during the T-wave period in a cardiac cycle in which the heart is particularly vulnerable to induction of ventricular fibrillation.
- an optional second time delay is provided to offset in time from the R-wave the delivery of the anti-tachyarrhythmia therapy.
- the second time delay is shorter than the approximately 250 millisecond interval between the R-wave and the T-wave that immediately follows.
- the anti-tachyarrhythmia therapy such as a countershock, is delivered to the atrium at step 520 after the second time delay has expired.
- the anti-tachyarrhythmia therapy comprises a countershock delivered synchronously to and optionally delayed from the ventricular activation (R-wave), such that the atrial countershock is delivered between an R-wave and a T-wave.
- FIG. 6 is a schematic illustration of one embodiment of an implantable device, such as implantable cardioverter-defibrillator 300 , for delivering anti-tachyarrhythmia therapy according to the present invention.
- Cardioverter-defibrillator 300 is illustrated in relation to a heart 305 to which it delivers therapy.
- Ventricular heart activity is sensed by a ventricular sensor such as electrodes 310 and 315 , which are independently electrically coupled through ventricular lead 320 to ventricular receiver 325 in cardioverter-defibrillator 300 .
- Atrial heart activity is sensed by an atrial sensor, such as atrial electrodes 330 and 335 , which are independently electrically coupled through atrial lead 340 to atrial receiver 345 in cardioverter-defibrillator 300 .
- the received ventricular and atrial signals may undergo further signal processing, including amplification, analog filtering, and analog-to-digital conversion in respective ventricular and atrial signal processing channels 350 and 355 before being provided to a controller 360 .
- Controller 360 typically includes a microprocessor and associated interface circuitry.
- Cardioverter-defibrillator 300 also includes: a battery 365 , for providing power to its various electrical components; transceiver 370 , for communication with external remote transceiver 375 ; atrial therapy circuit 380 , for providing anti-tachyarrhythmia therapy, such as an electrical countershock pulse, to the atrium of the heart 305 .
- Atrial lead 340 and atrial electrodes 330 and 335 are also electrically coupled to cardioverter-defibrillator 300 for delivery of the anti-tachyarrhythmia therapy from cardioverter-defibrillator 300 to the atrium of the heart 305 .
- Controller 360 is capable of detecting and distinguishing between the indications of ventricular tachyarrhythmia, as described above with respect to FIG. 1. Controller 360 is also capable of detecting the ventricular activations (R-waves) of the heart 305 , as described above with respect to FIG. 5. Controller 360 is also capable of detecting atrial activity and distinguishing between atrial tachyarrhythmia activity needing anti-tachyarrhythmia therapy, such as atrial fibrillation, and atrial tachyarrhythmia activity not requiring anti-tachyarrhythmia therapy. Controller 360 also includes a first timer 385 for measuring an elapsed time from an indication of abnormal susceptibility to ventricular tachyarrhythmia. The elapsed time of first timer 385 is compared to a first time delay value that is externally adjustably programmable from remote transceiver 375 through transceiver 370 .
- First timer 385 may be an analog timer or digital counter, or a software timer, or any other suitable timer implementation.
- the value of the first time delay is adjustably programmed by the physician to exceed the estimated time period of metabolic vulnerability for a patient following a recent indication of abnormal susceptibility to ventricular tachyarrhythmia.
- First timer 385 is reset at each indication of abnormal susceptibility to ventricular tachyarrhythmia, and in one embodiment, the first time delay is also adjusted to correspond to a value that is particularized to each type of indication of ventricular tachyarrhythmia, as described above with respect to FIG. 2.
- controller 360 When controller 360 detects an atrial tachyarrhythmia needing therapy, it provides anti-tachyarrhythmia therapy, such as a countershock, through atrial therapy circuit 380 , to the atrium when a sufficient time has elapsed since the last indication of abnormal susceptibility to ventricular tachyarrhythmia (i.e., when first timer 385 indicates that the first time delay has expired). If, upon detection of the atrial tachyarrhythmia, the first time delay has not expired, controller 360 waits until the first time delay 385 has expired.
- anti-tachyarrhythmia therapy such as a countershock
- controller 360 rechecks whether atrial tachyarrhythmia is still present, after waiting until the first time delay 385 has expired, before delivering anti-tachyarrhythmia therapy to the atrium, as described above with respect to FIG. 3.
- controller 360 is immediately capable of delivering subsequent atrial anti-tachyarrhythmia therapy, as described above with respect to FIGS. 1 - 2 .
- controller 360 resets first timer 385 after atrial anti-tachyarrhythmia therapy is delivered, such that subsequent atrial anti-tachyarrhythmia therapy is inhibited for a corresponding period of time, as described above with respect to FIG. 4.
- delivery of atrial anti-tachyarrhythmia therapy is itself defined as an indication of abnormal susceptibility to ventricular tachyarrhythmia having a separate corresponding first time delay value.
- controller 360 adjusts the first time delay accordingly, as described above with respect to FIG. 2.
- Controller 360 typically also includes synchronizer 390 for synchronizing delivery of the atrial anti-tachyarrhythmia therapy to a ventricular activation (R-wave) sensed by ventricular receiver 325 , as described above with respect to FIG. 5.
- synchronizer 390 includes a second timer for delaying the synchronous delivery of the atrial anti-tachyarrhythmia therapy for a second time delay, as described above with respect to FIG. 5.
- the present invention provides anti-tachyarrhythmia therapy to the atrium of the heart such that the risk of ventricular tachyarrhythmias, particularly that of life-threatening ventricular fibrillation, is minimized.
- the present invention recognizes that the heart is metabolically abnormally susceptible to reinduction of ventricular tachyarrhythmias during the time periods that follow indications of abnormal susceptibility to ventricular tachyarrhythmias.
- the present invention avoids atrial anti-tachyarrhythmia therapy, such as countershock treatment, during these vulnerable periods, thereby reducing the risk of inducing ventricular fibrillation.
Abstract
The invention provides anti-tachyarrhythmia therapy, such as a countershock, to an atrium needing treatment, but delays its delivery for a programmable period of time following an indication of susceptibility to ventricular tachyarrhythmia (VT). This reduces the risk of reinducing VT during a period in which the heart is abnormally metabolically vulnerable to VT, including ventricular fibrillation (VF). The delay time may be independently programmed for different indications of VT, and may be synchronized to and delayed from the R-wave. The delay time may be adjusted, such as to exceed one second, or even to exceed several hours, in order to accommodate the metabolic abnormal susceptibility of the particular patient in the wide range of patients needing treatment of atrial tachyarrhythmias.
Description
- This application claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Application No. 60/055,181, filed on Aug. 8, 1997, which is incorporated herein by reference.
- This invention relates generally to cardiac rhythm management devices and methods, and more particularly to an implantable device, such as a cardioverter-defibrillator, and method for ting atrial tachyarrhythmias.
- Atrial tachyarrhythmias are quite common, and are seen even in patients who are not acutely ill. One such atrial tachyarrhythmia, atrial fibrillation, does not usually pose an immediate threat to the patient's life, but prolonged atrial fibrillation can compromise patient hemodynamics. Inadequate blood flow due to atrial fibrillation may lead to blood clots, which increase the risk of strokes. Other symptoms may include palpitations of the heart, dizziness, or loss of consciousness.
- One method of treating atrial fibrillation is to deliver a countershock to terminate the arrhythmia. For example, the countershock may be applied via an external or inplantable defibrillator. However, this method of treating atrial fibrillation risks causing ventricular tachyarrhythmias, including life-threatening ventricular fibrillation.
- One method of reducing the risk of ventricular fibrillation is by synchronizing the delivery of a countershock to an electrical ventricular activation (R-wave) of the heart. There is, however, a need in the art to further reduce the risk of inducing ventricular tachyarrhythmias, such as life-threatening ventricular fibrillation, during the countershock treatment of comparatively less exigent atrial tachyarrhythmias.
- The present invention provides a method of applying anti-tachyarrhythmia therapy, such as a countershock, to the heart. From the atrium of the heart, atrial activity needing anti-tachyarrhythmia therapy is detected. Ventricular activity is monitored for an indication of abnormal susceptibility to ventricular tachyarrhythmia. Anti-tachyarrhythmia therapy is delivered to the atrium in response to the detected atrial tachyarrhythmia activity. But the atrial tachyarrhythmia therapy is delayed for a first time delay if the indication of abnormal susceptibility to ventricular tachyarrhythmia is detected.
- The present invention also provides an device, such as an implantable cardioverter-fibrillator, for delivering anti-tachyarrhythmia therapy to the heart. An atrial receiver receives an atrial heart activity signal from an atrium of the heart. A ventricular receiver receives a ventricular heart activity signal from the ventricle of the heart. A controller controls the delivery of the anti-tachyarrhythmia therapy to the atrium in response to the atrial heart activity signal indicating a need for the anti-tachyarrhythmia therapy. The controller includes a first timer for delaying the delivery, by a first time delay, of the anti-tachyarrhythmia therapy to the atrium in response to the ventricular heart activity signal indicating abnormal susceptibility to a ventricular tachyarrhythmia.
- In one embodiment, the countershock or other anti-tachyarrhythmia therapy is synchronized to or delayed from the R-wave. In another embodiment, following the indication of abnormal susceptibility to a ventricular tachyarrhythmia, the first timer is reset and the value of the first time delay is adjusted according to the particular type of indication of abnormal susceptibility to a ventricular tachyarrhythmia. The value of the first time delay can be programmed depending on the patient's vulnerability to ventricular tachyarrhythmia. The delay can be programmed to exceed approximately one second or approximately several hours. In one embodiment, the first timer is reset and the value of the first time delay is adjusted subsequent to delivery of an atrial countershock.
- The present invention delays delivery of atrial anti-tachyarrhythmia therapy when an indication of abnormal susceptibility to a ventricular tachyarrhythmia is present. As a result, the present invention reduces the risk of reinducing ventricular tachyarrhythmias, such as life-threatening ventricular fibrillation, which can be caused by the delivery of anti-tachyarrhythmia therapy to the atrium.
- In the drawings, like numerals describe substantially similar components throughout the several views.
- FIG. 1 is a flow chart illustrating one embodiment of a method of delivering an atrial countershock to treat tachyarrhythmias.
- FIG. 2 is a flow chart illustrating an alternate embodiment of the method illustrated in FIG. 1, in which a first time delay is adjusted according to a type of indication of abnormal susceptibility to ventricular tachyarrhythmia.
- FIG. 3 is a flow chart illustrating an alternate embodiment of the method illustrated in FIG. 1 that rechecks for atrial tachyarrhythmia after waiting until a first time delay expires.
- FIG. 4 is a flow chart illustrating an alternate embodiment of the method illustrated in FIG. 1, in which a first timer is reset after delivery of anti-tachyarrhythmia therapy to the atrium.
- FIG. 5 is a flow chart illustrating, in more detail, one embodiment of the step of delivering the atrial anti-tachyarrhythmia therapy in FIGS.1-4.
- FIG. 6 is a schematic diagram illustrating one embodiment of the present invention in relation to a heart to which it delivers therapy.
- In the following detailed description, reference is made to the accompanying drawings which form a part hereof, and in which is shown by way of illustration specific embodiments in which the invention may be practiced. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention, and it is to be understood that the embodiments may be combined, or that other embodiments may be utilized and that structural, logical and electrical changes may be made without departing from the spirit and scope of the present invention. The following detailed description is, therefore, not to be taken in a limiting sense, and the scope of the present invention is defined by the appended claims and their equivalents.
- The present invention provides anti-tachyarrhythmia therapy to an atrium of a heart. In this application, atrial tachyarrhythmias (ATs) are understood to comprise any atrial tachyarrhythmia including, but not limited to: sinus tachycardia, atrial flutter, atrial tachycardia, atrial fibrillation, AV nodal reentrant tachycardia. Ventricular tachyarrhythmias (VTs) are understood to comprise any ventricular tachyarrhythmia including, but not limited to, ventricular fibrillation (VF). Cardioversion and defibrillation are understood to refer generally to any treatment of a cardiac arrhythmia by an electrical countershock. Cardioverter and defibrillator are understood to refer generally to any device capable of treating a cardiac arrhythmia through an electrical countershock. Anti-tachyarrhythmia therapy is understood to comprise treatment of atrial tachyarrhythmia by electrical countershock, anti-tachyarrhythmia drugs, or anti-tachycardia pacing.
- The present invention provides anti-tachyarrhythmia therapy, such as countershock therapy, to the atrium of the heart such that the risk of ventricular tachyarrhythmias, particularly that of life-threatening ventricular fibrillation, is minimized. As described in detail below, the present invention recognizes time periods in which the ventricle of the heart may be abnormally susceptible to ventricular tachyarrhythmias, and avoids treatment of atrial tachyarrhythmias during these vulnerable periods.
- FIG. 1 is a flow chart illustrating one embodiment of the method according to the present invention. In FIG. 1, a first timer for measuring a first time delay is initially reset at
step 100. An atrium of the heart and a ventricle of the heart are concurrently and continuously monitored atsteps 110A-B. The atrium is monitored for any atrial tachyarrhythmia activity needing anti-tachyarrhythmia therapy, such as atrial fibrillation. The ventricle is monitored for any ventricular vulnerability, i.e. any indication of abnormal susceptibility to a ventricular tachyarrhythmia (VT), and particularly for abnormal susceptibility to ventricular fibrillation (VF). Sensed electrical indications of abnormal susceptibility to a ventricular tachyarrhythmia may include, but are not limited to: one or more premature ventricular contractions (PVCs); a particular number of premature ventricular contractions detected during a particular third period of time, such as, for example, 6 to 8 premature ventricular contractions occurring within an hour, a particular number of successive premature ventricular contractions; ventricular tachycardia bigeminy; non-sustained monomorphic or polymorphic ventricular tachycardia; sustained monomorphic or polymorphic ventricular tachycardia; and, ventricular fibrillation. - Indications of ventricular abnormal susceptibility are understood to include actual instances of ventricular tachyarrhythmia, including ventricular fibrillation, and any other indication of abnormal susceptibility to ventricular tachyarrhythmia For example, other suitable indications of abnormal susceptibility to ventricular tachyarrhythmia may include chemical or other indications. In one embodiment of the present invention, the actual delivery of atrial anti-tachyarrhythmia therapy, such as a countershock, is itself defined as an indication of abnormal susceptibility to ventricular tachyarrhythmia.
- Indications of abnormal susceptibility to ventricular tachyarrhythmia are understood not to include the T-wave time periods within a cardiac cycle during which the heart is normally particularly vulnerable to an external stimulus. However, in one embodiment of the present invention that is described below, such normal time periods of vulnerability are also avoided by the present invention. It is also understood that the indications of abnormal susceptibility to ventricular tachyarrhythmia are progammably adjustable by the physician. Thus, those indications of susceptibility to ventricular tachyarrhythmia that are considered abnormal may vary from patient to patient.
- One aspect of the present invention, is the recognition that such indications of abnormal susceptibility to ventricular tachyarrhythmia define time periods in which the heart is metabolically abnormally susceptible to induction of ventricular tachyarrhythmias, including life-threatening ventricular fibrillation. As described in detail below, the present invention avoids delivering anti-tachyarrhythmia therapy, such as countershock treatment, to the atrium during these vulnerable time periods.
- At
step 120, if the ongoing ventricular monitoring ofstep 110B provides no indication of abnormal susceptibility to ventricular tachyarrhythmia, the ongoing monitoring of the atrium and ventricle continues atconcurrent steps 110A-B. However, if abnormal susceptibility to ventricular tachyarrhythmia is indicated atstep 120, the first timer for measuring the first time delay is reset atstep 100 before the ongoing monitoring of the atrium and ventricle continues atconcurrent steps 110A-B. Thus, the first timer measures the elapsed time from the last indication of ventricular tachyarrhythmia, if any. - Similarly, at
step 140 if the ongoing atrial monitoring ofstep 110A provides no indication of a detected atrial tachyarrhythmia, the ongoing monitoring of the atrium and ventricle continues atconcurrent steps 110A-B. When, atstep 140, the atrial monitoring indicates detection of an atrial tachyarrhythmia, the present invention is typically capable of recognizing and distinguishing, atstep 145, between different forms of atrial tachyarrhythmia detected atstep 140, such that anti-tachyarrhythmia therapy is only delivered in response to particular forms of atrial tachyarrhythmia, e.g. atrial fibrillation (AF), as described below. If the detected atrial tachyarrhythmia does not indicate, atstep 145, that anti-tachyarrhythmia therapy should be delivered, the monitoring of the atrium and ventricle is continued atconcurrent steps 110A-B. - If, at
step 145, the detected atrial tachyarrhythmia indicates that anti-tachyarrhythmia therapy should be delivered, the first timer for measuring the first time delay is checked atstep 150. If the first time delay is expired (i.e., if the first timer's measurement of the elapsed time from the last indication of abnormal susceptibility to ventricular tachyarrhythmia, if any, exceeds the programmably adjustable value of the first time delay), a countershock or other anti-tachyarrhythmia therapy is delivered atstep 160 to the atrium in which the atrial tachyarrhythmia was detected. - If, however, the first time delay has not expired (i.e., if the first timer's measurement of the elapsed time from the last indication of abnormal susceptibility to ventricular tachyarrhythmia, if any, does not exceed the programmably adjustable value of the first time delay), anti-tachyarrhythmia therapy is delayed at
step 170 until the first time delay has expired. Atstep 170, after the first time delay expires, the countershock or other anti-tachyarrhythmia therapy is delivered to the atrium atstep 160. In this embodiment, the ongoing monitoring of the atrium and the ventricle may be optionally blanked during delivery of the anti-tachyarrhythmia therapy at step 110, but the ongoing monitoring continues following the delivery of the anti-tachyarrhythmia therapy to the atrium atstep 160. - As set forth above, the first time delay is typically programmably adjusted by the physician to accommodate the individual degree of metabolic vulnerability of the patient to ventricular tachyarrhythmia, including ventricular fibrillation. In the diverse patient population that is susceptible to atrial tachyarrhythmia, the metabolic vulnerability of the particular patient to ventricular tachyarrhythmia, including ventricular fibrillation, will vary widely. Thus, the duration of the first time delay, which follows the above-described indications of abnormal susceptibility to ventricular tachyarrhythmia, will also vary widely to accommodate this variability in the patient population.
- The period of metabolic vulnerability that the first time delay should exceed is typically longer than the duration of a cardiac cycle, i.e. time between successive heartbeats. Therefore, the first time delay is typically adjustably programmed to a value exceeding one second. The first time delay may even be programmed to exceed one hour or several hours for patients that are abnormally metabolically vulnerable to ventricular tachyarrhythmia, such as ventricular fibrillation, following recent indications of abnormal susceptibility to ventricular tachyarrhythmia.
- FIG. 2 is a flow chart illustrating one embodiment of the present invention in which the duration of the first time delay depends on the particular type of one or more recent particular indications of abnormal susceptibility to ventricular tachyarrhythmia. This embodiment allows the physician to independently program different values of the first time delay to correspond respectively to different types of indications of abnormal susceptibility to ventricular tachyarrhythmia. For example, one indication of abnormal susceptibility to ventricular tachyarrhythmia may be a single premature ventricular contraction, for which the physician may program a corresponding first time delay to be several seconds. Another indication of abnormal susceptibility to ventricular tachyarrhythmia may be an actual episode of ventricular fibrillation, for which the physician may program a corresponding first time delay to be several hours.
- The method illustrated in FIG. 2 closely follows that illustrated and described above with respect to FIG. 1, and like blocks or steps are indicated by the like numbers. However, in FIG. 2 at
step 200, the invention recognizes the type of the most recent indication of abnormal susceptibility to ventricular tachyarrhythmia, and sets the value of the first time delay accordingly, unless doing so would cut short an unexpired longer first time delay corresponding to a previous indication of abnormal susceptibility to ventricular tachyarrhythmia. The invention then resets the first timer atstep 100 before continuing the ongoing monitoring of the atrium and the ventricle atconcurrent steps 110A-B. - FIG. 3 is a flow chart illustrating an alternate embodiment of the method according to the present invention. The method illustrated in FIG. 3 closely follows that illustrated and described above with respect to FIG. 1, and like blocks or steps are indicated by the like numbers. However, in FIG. 3, after waiting until the first time delay expires at
step 170, the present invention rechecks whether atrial tachyarrhythmia is detected atstep 140. If atrial tachyarrhythmia is not present atstep 140, or is determined atstep 145 to be of a type not requiring treatment, the ongoing monitoring of the atrium and the ventricle is resumed atconcurrent steps 110A-B. If atrial tachyarrhythmia is still present atstep 140, and is determined atstep 145 to be of a type requiring treatment, the invention finds the first time delay to be expired atstep 150, and proceeds to deliver anti-tachyarrhythmia therapy, such as a countershock, to the atrium atstep 160. - FIG. 4 is a flow chart illustrating an alternate embodiment of the method according to the present invention. The method illustrated in FIG. 4 closely follows that illustrated and described above with respect to FIG. 1, and like blocks or steps are indicated by the like numbers. However, in FIG. 4, after the anti-tachyarrhythmia therapy, such as a countershock, is delivered to the atrium at
step 160, the timer for measuring the first time delay is reset atstep 100 before the ongoing monitoring of the atrium and ventricle continues atconcurrent steps 110A-B. Thus, according to the method illustrated in FIG. 4, subsequent atrial anti-tachyarrhythmia therapy is delayed by at least the first time delay regardless of whether or not ventricular tachyarrhythmia is indicated atstep 120. By contrast, according to the embodiment illustrated in FIG. 1, subsequent atrial anti-tachyarrhythmia therapy can be delivered immediately, i.e. without waiting for the duration of first time delay, if ventricular tachyarrhythmia is not indicated subsequent to a first delivery of atrial anti-tachyarrhythmia therapy. - In FIGS.1-4, delivery of the atrial anti-tachyarrhythmia therapy, such as a countershock, at
step 160 typically includes synchronizing the delivery to ventricular activations (R-waves) of the heart. FIG. 5 is a flow chart illustrating, by way of example, one embodiment of the details ofstep 160 in more detail. The method illustrated in FIG. 5 closely follows that illustrated and described above with resect to FIG. 1, and like blocks or steps are indicated by the like numbers. However, the additional details ofstep 160 that are illustrated in FIG. 5 may also be applicable to other embodiments of the present invention, such as those illustrated in FIGS. 1-4. - In FIG. 5, delivery of anti-tachyarrhythmia therapy at
step 160 includes synchronizing to one of the ventricular activations (R-waves) of the heart, at step 500. Such ventricular activations are detected during the ongoing monitoring of the ventricle atstep 110B. Synchronizing the delivery of the anti-tachyarrhythmia therapy to one of the ventricular activations reduces the risk of delivering a countershock to the heart during the T-wave period in a cardiac cycle in which the heart is particularly vulnerable to induction of ventricular fibrillation. Atstep 510, an optional second time delay is provided to offset in time from the R-wave the delivery of the anti-tachyarrhythmia therapy. In one embodiment, the second time delay is shorter than the approximately 250 millisecond interval between the R-wave and the T-wave that immediately follows. The anti-tachyarrhythmia therapy, such as a countershock, is delivered to the atrium atstep 520 after the second time delay has expired. In this embodiment, the anti-tachyarrhythmia therapy comprises a countershock delivered synchronously to and optionally delayed from the ventricular activation (R-wave), such that the atrial countershock is delivered between an R-wave and a T-wave. - FIG. 6 is a schematic illustration of one embodiment of an implantable device, such as implantable cardioverter-
defibrillator 300, for delivering anti-tachyarrhythmia therapy according to the present invention. Cardioverter-defibrillator 300 is illustrated in relation to aheart 305 to which it delivers therapy. Ventricular heart activity is sensed by a ventricular sensor such aselectrodes ventricular lead 320 toventricular receiver 325 in cardioverter-defibrillator 300. Atrial heart activity is sensed by an atrial sensor, such asatrial electrodes atrial lead 340 toatrial receiver 345 in cardioverter-defibrillator 300. - For the embodiment of the cardioverter-
defibrillator 300 illustrated in FIG. 6, the received ventricular and atrial signals may undergo further signal processing, including amplification, analog filtering, and analog-to-digital conversion in respective ventricular and atrialsignal processing channels controller 360.Controller 360 typically includes a microprocessor and associated interface circuitry. Cardioverter-defibrillator 300 also includes: abattery 365, for providing power to its various electrical components;transceiver 370, for communication with externalremote transceiver 375;atrial therapy circuit 380, for providing anti-tachyarrhythmia therapy, such as an electrical countershock pulse, to the atrium of theheart 305.Atrial lead 340 andatrial electrodes defibrillator 300 for delivery of the anti-tachyarrhythmia therapy from cardioverter-defibrillator 300 to the atrium of theheart 305. -
Controller 360 is capable of detecting and distinguishing between the indications of ventricular tachyarrhythmia, as described above with respect to FIG. 1.Controller 360 is also capable of detecting the ventricular activations (R-waves) of theheart 305, as described above with respect to FIG. 5.Controller 360 is also capable of detecting atrial activity and distinguishing between atrial tachyarrhythmia activity needing anti-tachyarrhythmia therapy, such as atrial fibrillation, and atrial tachyarrhythmia activity not requiring anti-tachyarrhythmia therapy.Controller 360 also includes afirst timer 385 for measuring an elapsed time from an indication of abnormal susceptibility to ventricular tachyarrhythmia. The elapsed time offirst timer 385 is compared to a first time delay value that is externally adjustably programmable fromremote transceiver 375 throughtransceiver 370. -
First timer 385 may be an analog timer or digital counter, or a software timer, or any other suitable timer implementation. The value of the first time delay is adjustably programmed by the physician to exceed the estimated time period of metabolic vulnerability for a patient following a recent indication of abnormal susceptibility to ventricular tachyarrhythmia.First timer 385 is reset at each indication of abnormal susceptibility to ventricular tachyarrhythmia, and in one embodiment, the first time delay is also adjusted to correspond to a value that is particularized to each type of indication of ventricular tachyarrhythmia, as described above with respect to FIG. 2. - When
controller 360 detects an atrial tachyarrhythmia needing therapy, it provides anti-tachyarrhythmia therapy, such as a countershock, throughatrial therapy circuit 380, to the atrium when a sufficient time has elapsed since the last indication of abnormal susceptibility to ventricular tachyarrhythmia (i.e., whenfirst timer 385 indicates that the first time delay has expired). If, upon detection of the atrial tachyarrhythmia, the first time delay has not expired,controller 360 waits until thefirst time delay 385 has expired. In one embodiment,controller 360 rechecks whether atrial tachyarrhythmia is still present, after waiting until thefirst time delay 385 has expired, before delivering anti-tachyarrhythmia therapy to the atrium, as described above with respect to FIG. 3. In another embodiment,controller 360 is immediately capable of delivering subsequent atrial anti-tachyarrhythmia therapy, as described above with respect to FIGS. 1-2. In another embodiment,controller 360 resetsfirst timer 385 after atrial anti-tachyarrhythmia therapy is delivered, such that subsequent atrial anti-tachyarrhythmia therapy is inhibited for a corresponding period of time, as described above with respect to FIG. 4. In one embodiment, delivery of atrial anti-tachyarrhythmia therapy is itself defined as an indication of abnormal susceptibility to ventricular tachyarrhythmia having a separate corresponding first time delay value. In this embodiment, after delivery of atrial anti-tachyarrhythmia therapy,controller 360 adjusts the first time delay accordingly, as described above with respect to FIG. 2. -
Controller 360 typically also includessynchronizer 390 for synchronizing delivery of the atrial anti-tachyarrhythmia therapy to a ventricular activation (R-wave) sensed byventricular receiver 325, as described above with respect to FIG. 5. In one embodiment,synchronizer 390 includes a second timer for delaying the synchronous delivery of the atrial anti-tachyarrhythmia therapy for a second time delay, as described above with respect to FIG. 5. - Thus, the present invention provides anti-tachyarrhythmia therapy to the atrium of the heart such that the risk of ventricular tachyarrhythmias, particularly that of life-threatening ventricular fibrillation, is minimized. The present invention recognizes that the heart is metabolically abnormally susceptible to reinduction of ventricular tachyarrhythmias during the time periods that follow indications of abnormal susceptibility to ventricular tachyarrhythmias. The present invention avoids atrial anti-tachyarrhythmia therapy, such as countershock treatment, during these vulnerable periods, thereby reducing the risk of inducing ventricular fibrillation.
- It should be understood that the present invention may be implemented, for example, in a cardioverter-defibrillator that provides anti-tachyarrhythmia therapy, such as a countershock, to the atrium only. The present invention may also be implemented as part of a dual-chamber cardioverter-defibrillator that provides anti-tachyarrhythmia therapy, such as a countershock, to both the atrium and ventricle. Also, the anti-tachyarrhythmia therapy may also include therapy other than countershocks without departing from the scope and spirit of the present invention. For example, anti-tachycardia pacing or drug delivery therapy could be similarly delayed from the above-described indications of ventricular tachyarrhythmias. In another example, bradycardia pacing therapy could be combined with the above-described functionality of the present invention.
- It is to be understood that the above description is intended to be illustrative, and not restrictive. Many other embodiments will be apparent to those of skill in the art upon reviewing the above description. The scope of the invention should, therefore, be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled.
Claims (51)
1. A method of applying anti-tachyarrhythmia therapy to a heart, the method including the steps of:
detecting, from an atrium of the heart atrial tachyarrhythmia activity indicative of a need for the anti-tachyarrhythmia therapy;
monitoring ventricular activity of the heart for an indication of abnormal susceptibility to a ventricular tachyarrhythmia; and
applying the anti-tachyarrhythmia therapy to the atrium in response to the detected atrial tachyarrhythmia activity, but delaying the application of the anti-tachyarrhythmia therapy for a first time delay if the indication of abnormal susceptibility to the ventricular tachyarrhythmia is detected.
2. The method of , further comprising the step of detecting ventricular activations of the heart.
claim 1
3. The method of , wherein the step of applying the anti-tachyarrhythmia therapy is synchronized to one of the detected ventricular activations of the heart.
claim 2
4. The method of , wherein the step of applying the anti-tachyarrhythmia therapy is delayed for a second time delay from the one of the detected ventricular activations of the heart.
claim 3
5. The method of , wherein the second time delay is shorter than an interval between the one of the detected ventricular activations of the heart and a T-wave immediately following the one of the detected ventricular activations of the heart.
claim 4
6. The method of , wherein the first time delay exceeds approximately one second.
claim 1
7. The method of , wherein the first time delay exceeds approximately one hour.
claim 1
8. The method of , wherein the fist time delay exceeds approximately several hours.
claim 1
9. The method of , wherein the first time delay exceeds a period in which the ventricle is abnormally susceptible to tachyarrhythmia resulting from the anti-tachyarrhythmia therapy applied to the atrium.
claim 1
10. The method of , wherein the first time delay is adjustable.
claim 1
11. The method of , wherein the first time delay is programmable based upon an abnormal susceptibility of an individual patient to ventricular tachyarrhythmia in response to the anti-tachyarrhythmia therapy applied to the atrium.
claim 10
12. The method of , wherein the first time delay depends on the type of the indication of abnormal susceptibility to the ventricular tachyarrhythmia.
claim 1
13. The method of , wherein the first time delay is adjusted subsequent to the step of applying the anti-tachyarrhythmia therapy to the atrium.
claim 1
14. The method of , wherein the indication of abnormal susceptibility to the ventricular tachyarrhythmia includes at least one premature ventricular contraction.
claim 1
15. The method of , wherein the indication of abnormal susceptibility to the ventricular tachyarrhythmia includes a number of premature ventricular contractions detected over a third period of time.
claim 14
16. The method of , wherein the indication of abnormal susceptibility to the ventricular tachyarrhythmia includes a number of successive premature ventricular contractions.
claim 14
17. The method of , wherein the indication of abnormal susceptibility to the ventricular tachyarrhythmia includes non-sustained ventricular tachycardia.
claim 1
18. The method of , wherein the indication of abnormal susceptibility to the ventricular tachyarrhythmia includes ventricular tachycardia.
claim 1
19. The method of , wherein the indication of abnormal susceptibility to the ventricular tachyarrhythmia includes ventricular fibrillation.
claim 1
20. The method of , wherein the indication of abnormal susceptibility to the ventricular tachyarrhythmia is chemical.
claim 1
21. The method of , wherein the indication of abnormal susceptibility to the ventricular tachyarrhythmia is anti-tachyarrhythmia therapy that was previously delivered to the heart.
claim 1
22. The method of , wherein the anti-tachyarrhythmia therapy includes an electrical countershock.
claim 1
23. The method of , wherein the anti-tachyarrhythmia therapy includes delivery of an anti-tachyarrhythmia drug.
claim 1
24. The method of , wherein the anti-tachyarrhythmia therapy includes anti-tachycardia pacing.
claim 1
25. A method of applying anti-tachyarrhythmia therapy to a heart, the method including the steps of:
detecting, from an atrium of the heart, atrial tachyarrhythmia activity indicative of a need for the anti-tachyarrhythmia therapy; and
applying anti-tachyarrhythmia therapy to the atrium in response to the detected atrial tachyarrhythmia activity, but delaying the application of the anti-tachyarrhythmia therapy for at least a time period in which a ventricle of the heart is abnormally susceptible to fibrillation.
26. An implantable device for delivering anti-tachyarrhythmia therapy to a heart, the device comprising:
an atrial receiver for receiving an atrial heart activity signal from an atrium of the heart;
a ventricular receiver for receiving a ventricular heart activity signal from a ventricle of the heart;
an atrial therapy circuit for delivering anti-tachyarrhythmia therapy to the atrium; and
a controller, coupled to each of the atrial therapy circuit and the atrial and ventricular receivers, for controlling the delivery of the anti-tachyarrhythmia therapy to the atrium in response to the atrial heart activity signal indicating a need for anti-tachyarrhythmia therapy, and wherein the controller includes a first timer for delaying, for a first time delay, the delivery of the anti-tachyarrhythmia therapy to the atrium by a first time delay in response to the ventricular heart activity signal that includes an indication of abnormal susceptibility to a ventricular tachyarrhythmia.
27. The device of , wherein the anti-tachyarrhythmia therapy includes an electrical countershock.
claim 26
28. The device of , wherein the anti-tachyarrhythmia therapy includes delivery of an anti-tachyarrhythmia drug.
claim 26
29. The device of , wherein the anti-tachyarrhythmia therapy includes anti-tachycardia pacing.
claim 26
30. The device of , wherein the controller includes a synchronizer for synchronizing the delivery of the anti-tachyarrhythmia therapy to the ventricular heart activity signal indicating a ventricular activation.
claim 26
31. The device of , wherein the controller includes a second timer for delaying the delivery of the anti-tachyarrhythmia therapy, for a second time delay, from the ventricular activation to which it is synchronized.
claim 30
32. The device of , wherein the second time delay is shorter than an interval between the ventricular activation to which the anti-tachyarrhythmia therapy is synchronized and a T-wave immediately following the ventricular activation to which the anti-tachyarrhythmia therapy is synchronized.
claim 31
33. The device of , wherein the first time delay exceeds approximately one second.
claim 26
34. The device of , wherein the first time delay exceeds approximately one hour.
claim 26
35. The device of , wherein the first time delay exceeds approximately several hours.
claim 26
36. The device of , wherein the first time delay exceeds a period in which the ventricle is abnormally susceptible to tachyarrhythmia from the anti-tachyarrhythmia therapy applied to the atrium.
claim 26
37. The device of , wherein the first time delay is adjustable.
claim 26
38. The device of , wherein the first time delay is programmable based upon an abnormal susceptibility of an individual patient to ventricular tachyarrhythmia in response to the anti-tachyarrhythmia therapy applied to the atrium.
claim 37
39. The device of , wherein the first time delay depends on the type of the indication of abnormal susceptibility to the ventricular tachyarrhythmia.
claim 26
40. The device of , wherein the first time delay is adjusted subsequent to the delivery of the anti-tachyarrhythmia therapy to the atrium.
claim 26
41. The device of , wherein the indication of abnormal susceptibility to the ventricular tachyarrhythmia includes at least one premature ventricular contraction.
claim 26
42. The device of , wherein the indication of abnormal susceptibility to the ventricular tachyarrhythmia includes at number of premature ventricular contractions detected over a third period of time.
claim 41
43. The device of , wherein the indication of abnormal susceptibility to the ventricular tachyarrhythmia includes a number of successive premature ventricular contractions.
claim 41
44. The device of , wherein the indication of abnormal susceptibility to the ventricular tachyarrhythmia includes a non-sustained ventricular tachycardia.
claim 26
45. The device of , wherein the indication of abnormal susceptibility to the ventricular tachyarrhythmia includes a ventricular tachycardia.
claim 26
46. The device of , wherein the indication of abnormal susceptibility to the ventricular tachyarrhythmia includes a ventricular fibrillation.
claim 26
47. The device of , wherein the indication of abnormal susceptibility to the ventricular tachyarrhythmia is chemical.
claim 26
48. The device of , wherein the indication of abnormal susceptibility to the ventricular tachyarrhythmia is anti-tachyarrhythmia therapy that was previously delivered to the heart.
claim 26
49. The device of , further comprising:
claim 26
an atrial sensor for detecting the atrial heart activity signal;
a ventricular sensor for detecting the ventricular heart activity signal;
an atrial lead for coupling the atrial sensor to the atrial receiver, and
a ventricular lead for coupling the ventricular sensor to the ventricular receiver.
50. The device of , wherein the atrial sensor comprises a pair of electrodes for detecting the atrial heart activity signal and for coupling the anti-tachyarrhythmia therapy to the atrium.
claim 49
51. The device of , wherein the ventricular sensor comprises a pair of electrodes for detecting the ventricular heart activity signal.
claim 49
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/852,513 US6393321B2 (en) | 1997-08-08 | 2001-05-10 | Device and method providing atrial anti-tachyarrhythmia therapy |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5518197P | 1997-08-08 | 1997-08-08 | |
US09/130,090 US6091991A (en) | 1998-08-07 | 1998-08-07 | Method providing atrial anti-tachyarrhythmia therapy |
US09/558,937 US6292696B1 (en) | 1997-08-08 | 2000-04-26 | Device and method providing atrial anti-tachyarrhythmia therapy |
US09/852,513 US6393321B2 (en) | 1997-08-08 | 2001-05-10 | Device and method providing atrial anti-tachyarrhythmia therapy |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/558,937 Continuation US6292696B1 (en) | 1997-08-08 | 2000-04-26 | Device and method providing atrial anti-tachyarrhythmia therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
US20010021863A1 true US20010021863A1 (en) | 2001-09-13 |
US6393321B2 US6393321B2 (en) | 2002-05-21 |
Family
ID=22443010
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/130,090 Expired - Fee Related US6091991A (en) | 1997-08-08 | 1998-08-07 | Method providing atrial anti-tachyarrhythmia therapy |
US09/558,937 Expired - Lifetime US6292696B1 (en) | 1997-08-08 | 2000-04-26 | Device and method providing atrial anti-tachyarrhythmia therapy |
US09/852,513 Expired - Lifetime US6393321B2 (en) | 1997-08-08 | 2001-05-10 | Device and method providing atrial anti-tachyarrhythmia therapy |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/130,090 Expired - Fee Related US6091991A (en) | 1997-08-08 | 1998-08-07 | Method providing atrial anti-tachyarrhythmia therapy |
US09/558,937 Expired - Lifetime US6292696B1 (en) | 1997-08-08 | 2000-04-26 | Device and method providing atrial anti-tachyarrhythmia therapy |
Country Status (1)
Country | Link |
---|---|
US (3) | US6091991A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070293894A1 (en) * | 2006-06-16 | 2007-12-20 | Yunlong Zhang | Method and apparatus for detecting non-sustaining ventricular tachyarrhythmia |
US20080154318A1 (en) * | 2006-12-21 | 2008-06-26 | Marco Albus | Implantable medical device |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10064597A1 (en) | 2000-12-18 | 2002-06-27 | Biotronik Mess & Therapieg | Device for treating fibrillation of at least one chamber of a heart |
CZ20033347A3 (en) * | 2001-06-18 | 2004-04-14 | The Procter & Gamble Company | Cosmetic compositions containing separated color domains and associated processes |
US20030003065A1 (en) * | 2001-06-18 | 2003-01-02 | The Procter & Gamble Company | Cosmetic compositions exhibiting characteristic first derivative spectral curves and associated methods |
US7110811B2 (en) * | 2002-12-30 | 2006-09-19 | Cardiac Pacemakers, Inc. | Method and apparatus for atrial tachyarrhythmia cardioversion |
US7162300B2 (en) * | 2003-01-13 | 2007-01-09 | Medtronic, Inc. | Synchronized atrial anti-tachy pacing system and method |
US7536224B2 (en) * | 2003-04-30 | 2009-05-19 | Medtronic, Inc. | Method for elimination of ventricular pro-arrhythmic effect caused by atrial therapy |
US8175702B2 (en) | 2004-11-04 | 2012-05-08 | The Washington University | Method for low-voltage termination of cardiac arrhythmias by effectively unpinning anatomical reentries |
CA2673971C (en) * | 2006-11-13 | 2016-07-19 | Washington University Of St. Louis | Cardiac pacing using the inferior nodal extension |
US8560066B2 (en) | 2007-12-11 | 2013-10-15 | Washington University | Method and device for three-stage atrial cardioversion therapy |
CA2709287C (en) * | 2007-12-11 | 2018-04-24 | Washington University Of St. Louis | Method and device for low-energy termination of atrial tachyarrhythmias |
US8874208B2 (en) | 2007-12-11 | 2014-10-28 | The Washington University | Methods and devices for three-stage ventricular therapy |
US20120143294A1 (en) * | 2010-10-26 | 2012-06-07 | Medtronic Adrian Luxembourg S.a.r.l. | Neuromodulation cryotherapeutic devices and associated systems and methods |
US8473051B1 (en) | 2010-12-29 | 2013-06-25 | Cardialen, Inc. | Low-energy atrial cardioversion therapy with controllable pulse-shaped waveforms |
US10905884B2 (en) | 2012-07-20 | 2021-02-02 | Cardialen, Inc. | Multi-stage atrial cardioversion therapy leads |
US8868178B2 (en) | 2012-12-11 | 2014-10-21 | Galvani, Ltd. | Arrhythmia electrotherapy device and method with provisions for mitigating patient discomfort |
ES2713231T3 (en) | 2015-02-06 | 2019-05-20 | Cardiac Pacemakers Inc | Systems for the safe supply of electrical stimulation therapy |
CN111107899B (en) | 2017-09-20 | 2024-04-02 | 心脏起搏器股份公司 | Implantable medical device with multiple modes of operation |
DE102019110284A1 (en) | 2019-04-18 | 2020-10-22 | Biotronik Se & Co. Kg | Implantable arrangement for stimulating a human or animal heart |
US20220305256A1 (en) | 2020-12-01 | 2022-09-29 | Cardialen Inc. | Systems, devices, and related methods for cardiac arrhythmia therapy |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2248020B1 (en) * | 1973-10-18 | 1977-05-27 | Pequignot Michel | |
US4593695A (en) * | 1984-02-24 | 1986-06-10 | Vitafin N.V. | Pacemaker with improved tachycardia treatment means and method |
US5156148A (en) * | 1987-10-06 | 1992-10-20 | Leonard Bloom | System for treating a malfunctioning heart |
US5514164A (en) * | 1994-03-25 | 1996-05-07 | Pacesetter, Inc. | DDD pacing response to atrial tachyucardia and retrograde conduction |
US5690686A (en) | 1996-04-30 | 1997-11-25 | Medtronic, Inc. | Atrial defibrillation method |
US5792205A (en) * | 1996-10-21 | 1998-08-11 | Intermedics, Inc. | Cardiac pacemaker with bidirectional communication |
US5792183A (en) * | 1997-01-27 | 1998-08-11 | Cardiac Pacemakers, Inc. | Combination pacemaker and defibrillator having dynamic ventricular refractory period |
US5968079A (en) | 1998-03-18 | 1999-10-19 | Medtronic, Inc. | Method and apparatus for diagnosis and treatment of arrhythmias |
-
1998
- 1998-08-07 US US09/130,090 patent/US6091991A/en not_active Expired - Fee Related
-
2000
- 2000-04-26 US US09/558,937 patent/US6292696B1/en not_active Expired - Lifetime
-
2001
- 2001-05-10 US US09/852,513 patent/US6393321B2/en not_active Expired - Lifetime
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070293894A1 (en) * | 2006-06-16 | 2007-12-20 | Yunlong Zhang | Method and apparatus for detecting non-sustaining ventricular tachyarrhythmia |
US7689282B2 (en) * | 2006-06-16 | 2010-03-30 | Cardiac Pacemakers, Inc. | Method and apparatus for detecting non-sustaining ventricular tachyarrhythmia |
US20100152803A1 (en) * | 2006-06-16 | 2010-06-17 | Yunlong Zhang | Method and apparatus for detecting non-sustaining ventricular tachyarrhythmia |
US8265751B2 (en) | 2006-06-16 | 2012-09-11 | Cardiac Pacemakers, Inc. | Method and apparatus for detecting non-sustaining ventricular tachyarrhythmia |
US20080154318A1 (en) * | 2006-12-21 | 2008-06-26 | Marco Albus | Implantable medical device |
Also Published As
Publication number | Publication date |
---|---|
US6393321B2 (en) | 2002-05-21 |
US6292696B1 (en) | 2001-09-18 |
US6091991A (en) | 2000-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6393321B2 (en) | Device and method providing atrial anti-tachyarrhythmia therapy | |
US6047210A (en) | Cardioverter and method for cardioverting an atrial tachyarrhythmia while maintaining atrial pacing | |
EP1075313B1 (en) | Method and apparatus for treatment of arrhythmias | |
JP2601762B2 (en) | Cardioverter defibrillator | |
CA2298288C (en) | Improved atrial defibrillator, lead systems and method | |
EP1501600B1 (en) | Combined anti-tachycardia pacing (atp) and high voltage therapy for treating ventricular arrhythmias | |
EP0770409B1 (en) | An implantable atrial defibrillator and system having multiple channel electrogram telemetry | |
EP0594271B1 (en) | Atrial defibrillator for providing synchronized delayed cardioversion | |
US7333855B2 (en) | Method and apparatus for determining oversensing in a medical device | |
EP1021222B1 (en) | Atrial cardioverter with window based atrial tachyarrhythmia detection system | |
CA2150047C (en) | Atrial defibrillator and method providing dual reset of an interval timer | |
EP1109597B1 (en) | Cardioverter for cardioverting an atrial tachyarrhythmia in the presence of atrial pacing | |
US20030135242A1 (en) | Forced deceleration algorithm for synchronization of atrial cardioversion shock and technique for the implementation | |
WO2006060497A1 (en) | Method and apparatus for determining oversensing in a medical device | |
JP2004536678A (en) | Method and apparatus for controlling delivery of high voltage and anti-tachycardia pacing therapy in an implantable medical device | |
EP0724893B1 (en) | An implantable atrial defibrillator having delayed intervention therapy | |
CA2183492A1 (en) | Cardiac assist device having muscle augmentation after confirmed arrhythmia | |
US20020147471A1 (en) | Cardiac rhythm management system synchronizing atrial shock to ventricular depolarization based on sensing refractory |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FPAY | Fee payment |
Year of fee payment: 12 |